Top

Published in:

01-02-2018 | Editorial

Rocuronium bromide: clinical application of single-dose pharmacokinetic models to continuous infusion

Author: Yutaka Oda

Published in: Journal of Anesthesia | Issue 1/2018

Excerpt

Rocuronium has become the neuromuscular blocking agent of first choice immediately after its launch in Japan. Although having fast onset as well as intermediate duration of action and a lack of prolonged effects, which make it suitable for continuous infusion [1, 2], intermittent administration has been standardly used, probably because of its large inter-individual variations of action after bolus and continuous administration [1]. Its neuromuscular blocking effect may also be influenced by the amount of muscle and sensitivity to neuromuscular receptors as well as its plasma concentration, which make it difficult to maintain an adequate level of neuromuscular blockade by avoiding excessive dosing. Therefore, the establishment of an adequate continuous administration regimen is required. …

McCoy EP, Mirakhur RK, Maddineni VR, Wierda JM, Proost JH. Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. Br J Anaesth. 1996;76:29–33.CrossRefPubMed

Miller DR, Wherrett C, Hull K, Watson J, Legault S. Cumulation characteristics of cisatracurium and rocuronium during continuous infusion. Can J Anaesth. 2000;47:943–9.CrossRefPubMed

Kajiura A, Nagata O, Takizawa Y, Nakatomi T, Kodera S, Murayama T. A large individual variation in both the infusion rate and the blood concentration of rocuronium necessary for obtain adequate surgical muscle relaxation during total intravenous anesthesia with propofol and remifentanil. J Anesth. 2015;29:9–14.CrossRefPubMed

Takagi S, Ozaki M, Iwasaki H, Hatano Y, Takeda J. Effects of sevoflurane and propofol on neuromuscular blocking action of Org 9426 (rocuronium bromide) infused continuously in Japanese patients. Masui. 2006;55:963–70.PubMed

Wierda JM, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth. 1991;38:430–5.CrossRefPubMed

Moriyama T, Matsunaga A, Nagata O, Enohata K, Kamikawaji T, Uchino E, Kanmura Y. Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. J Anesth. 2015;29:593–9.CrossRefPubMed

Szenohradszky J, Fisher DM, Segredo V, Caldwell JE, Bragg P, Sharma ML, Gruenke LD, Miller RD. Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiology. 1992;77:899–904.CrossRefPubMed

Alvarez-Gomez JA, Estelles ME, Fabregat J, Perez F, Brugger AJ. Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. Eur J Anaesthesiol Suppl. 1994;9:53–6.PubMed

Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, Fitzpatrick KT. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth. 1993;71:222–6.CrossRefPubMed

10.

Magorian T, Wood P, Caldwell J, Fisher D, Segredo V, Szenohradszky J, Sharma M, Gruenke L, Miller R. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg. 1995;80:754–9.PubMed

11.

Wierda JM, Proost JH, Schiere S, Hommes FD. Pharmacokinetics and pharmacokinetic/dynamic relationship of rocuronium bromide in humans. Eur J Anaesthesiol Suppl. 1994;9:66–74.PubMed

12.

Sasakawa T, Masui K, Kazama T, Iwasaki H. The predictive ability of six pharmacokinetic models of rocuronium developed using a single bolus: evaluation with bolus and continuous infusion regimen. J Anesth. 2016;30:620–7.CrossRefPubMed

13.

Motsch J, Leuwer M, Pfau M, Zimmerman J, Martin E. Time course of action and recovery of rocuronium bromide in children during halothane anaesthesia—a preliminary report. Eur J Anaesthesiol Suppl. 1994;9:75–7.PubMed

14.

Yano T, Taniguchi M, Tsuneyoshi I. Continuous rocuronium administration for tracheomalacia. J Anesth. 2015;29:978.CrossRefPubMed

15.

Kotake Y, Ochiai R, Suzuki T, Ogawa S, Takagi S, Ozaki M, Nakatsuka I, Takeda J. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg. 2013;117:345–51.CrossRefPubMed

Title: Rocuronium bromide: clinical application of single-dose pharmacokinetic models to continuous infusion
Author: Yutaka Oda
Publication date: 01-02-2018
Publisher: Springer Japan
Published in: Journal of Anesthesia / Issue 1/2018
Print ISSN: 0913-8668
Electronic ISSN: 1438-8359
DOI: https://doi.org/10.1007/s00540-017-2401-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Rocuronium bromide: clinical application of single-dose pharmacokinetic models to continuous infusion

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Preoperative pulmonary function tests before low-risk surgery in Japan: a retrospective cohort study using a claims database

Murphy’s law and Murphy eyes

Postoperative mortality and morbidity following non-cardiac surgery in a healthy patient population

Intraoperative administration of dexmedetomidine reduced the postoperative catheter-related bladder discomfort and pain in patients undergoing lumbar microdiscectomy

Cerebrovascular CO2 reactivity during isoflurane-nitrous oxide anesthesia in patients with chronic renal failure

Comparing ultrasound-guided and fiberscope-guided intubation